Does sermorelin work: Frequently asked questions

Re-evaluate with repeat IGF-1 testing and consider a provocative GH test while on sermorelin therapy. If IGF-1 levels haven't risen and stimulated GH remains low, the patient is a sermorelin non-responder. Likely due to insufficient pituitary reserve. And should transition to rhGH. Historical trial data showed that responders demonstrated IGF-1 increases within 8–12 weeks; if that doesn't occur by month three, continuing sermorelin is unlikely to change the outcome. Non-response isn't treatment failure. It's diagnostic information that the underlying pathology is more severe than initial testing suggested.

Sermorelin is a reasonable option if the child has documented partial GHD and intact pituitary anatomy on imaging. Frame the decision clearly: sermorelin works with the child's physiology by amplifying endogenous GH pulses, but it will not match the growth outcomes of rhGH in moderate-to-severe GHD. The 1993 JCEM trial showed sermorelin-treated children gained an average of 4.1 cm/year, while historical rhGH controls in similar populations gained 6–8 cm/year. If maximising catch-up growth is the priority, rhGH is superior. If the family values working within the body's regulatory systems and accepts a potentially slower growth trajectory, sermorelin is a medically sound choice. But only if the child's pituitary can respond.

This reflects physiological tachyphylaxis. Each GH pulse elevates IGF-1 and somatostatin tone, which attenuates subsequent sermorelin responses until several hours pass. Space doses at least 4–6 hours apart to allow somatostatin clearance. Alternatively, combine sermorelin with a ghrelin mimetic like GHRP-2, which partially overrides somatostatin inhibition through a distinct receptor pathway. This combination produces larger-amplitude pulses even with shorter inter-dose intervals.

Administer a second dose 4–6 hours later to rule out timing error or transient somatostatin suppression. Absent response suggests either primary pituitary failure (somatotroph depletion or GHRH receptor downregulation) or methodological error. Confirm the peptide was stored correctly and reconstituted within 14 days. A flat response despite correct protocol indicates the subject lacks sufficient somatotroph reserve capacity, which is itself a valid experimental finding in aging or disease models.

Subcutaneous administration delays absorption compared to IV, shifting peak response to 45–90 minutes post-dose. Sampling every 15 minutes captures the pulse regardless of minor kinetic variation. Individual pharmacokinetic differences. Body composition, injection site blood flow, prior peptide exposure. Can shift timing by 10–20 minutes without indicating peptide failure. The pulse width and AUC matter more than exact peak timing for most experimental endpoints.

Discard it. Peptide bonds degrade rapidly above 8°C, with >40% potency loss documented after 72 hours at 25°C. The peptide may appear unchanged visually, but structural degradation is irreversible and undetectable without lab analysis. Using compromised peptide introduces a confounding variable. You can't determine if lack of GH response is due to biological non-responsiveness or peptide degradation. Replace the vial and refrigerate immediately after reconstitution.

Start with a sermorelin stimulation test to assess residual GH secretory capacity before committing to long-term therapy. If peak GH response exceeds 5 ng/mL post-sermorelin, the child likely retains enough somatotroph function to benefit from therapeutic sermorelin dosing. If peak GH remains below 3 ng/mL, the pituitary tissue may be too compromised to respond adequately, making rhGH the more reliable choice. The stimulation test is a low-risk functional assessment that provides actionable data. And in the pre-2008 era, it was standard protocol at academic pediatric endocrine centers for exactly this decision point.

No. Sermorelin's short half-life and preservation of negative feedback prevent receptor downregulation observed with sustained GH agonists. A 28-day rodent study published in the Journal of Endocrinology showed consistent GH pulse amplitude across the entire treatment period with daily sermorelin dosing. This contrasts with MK-677 or exogenous GH, both of which suppress endogenous production within 72 hours of continuous use. For chronic studies, sermorelin maintains physiological responsiveness indefinitely.

Sermorelin is not orally bioavailable. Gastric proteases degrade the peptide before systemic absorption. Intranasal delivery has shown limited success in small-scale studies, but bioavailability remains <5% compared to subcutaneous administration. For non-invasive GH axis research, consider MK-677 (oral ghrelin mimetic) or alternative peptide formulations designed for mucosal absorption, though these alter the mechanism and feedback dynamics compared to sermorelin.

Verify peptide integrity first. Request third-party mass spectrometry or HPLC analysis to confirm amino acid sequence and purity. Temperature excursion during shipping, improper reconstitution technique, or prolonged storage above 2°C are the most common causes of peptide inactivity. If the peptide tests pure, consider somatotroph hyporesponsiveness: aging animal models or subjects with prior exogenous GH exposure may show blunted GHRH receptor sensitivity. Co-administration with a GHRP (ghrelin receptor agonist) can bypass GHRH receptor limitations and confirm pituitary GH capacity.